Management of focal-onset seizures: An update on drug treatment

Drugs

Volumn 66, Issue 13, 2006, Pages 1701-1725

  Johannessen, Svein I ^a   Ben Menachem, Elinor ^b  

^a National Center for Epilepsy   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; CLOBAZAM; CLONAZEPAM; DRUG METABOLITE; ENZYME INDUCING AGENT; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RIFAMPICIN; SERTRALINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABNORMAL THINKING; AGE DISTRIBUTION; AGGRESSION; AMENORRHEA; ANOREXIA; ANOREXIA NERVOSA; ANXIETY; APLASTIC ANEMIA; AREA UNDER THE CURVE; ASTHENIA; ATAXIA; BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONNECTIVE TISSUE DISEASE; CONTROLLED DRUG RELEASE; CROSS ALLERGY; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; EMOTIONAL DISORDER; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HAIR LOSS; HEADACHE; HUMAN; HYPONATREMIA; INSOMNIA; IRRITABILITY; MOOD CHANGE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; NEURORADIOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREGNANCY; PSYCHOSIS; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; TREMOR; UNSPECIFIED SIDE EFFECT; VISUAL FIELD DEFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; DRUG DESIGN; DRUG INDUSTRY; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; HUMANS;

EID: 33748885765     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666130-00004     Document Type: Review

References (170)

1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489-501
2. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99
3. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005; 46: 470-2
4. Loddenkemper T, Kellinghaus C, Wyllie E, et al. A proposal for a five-dimensional patient-oriented epilepsy classification. Epileptic Disord 2005; 7: 308-20
5. Battaglia A, Guerrini R. Chromosomal disorders associated with epilepsy. Epileptic Disord 2005; 7: 181-92
6. Ottman R. Analysis of genetically complex epilepsies. Epilepsia 2005; 46 Suppl. 19: 7-14
7. Sander T. The genetics of idiopathic generalized epilepsy: implications for the understanding of its aetiology. Mol Med Today 1996; 2: 173-80
8. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940-1980. Epilepsia 1991; 32: 429-45
9. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993; 34: 453-68
10. Salanova V, Markand O, Worth R. Temporal lobe epilepsy: analysis of patients with dual pathology. Acta Neurol Scand 2004; 109: 126-31
11. Bast T, Ramantani G, Seitz A, et al. Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults. Acta Neurol Scand 2006; 113: 72-81
12. Eriksson SH, Nordborg C, Rydenhag B, et al. Parenchymal lesions in pharmacoresistant temporal lobe epilepsy: dual and multiple pathology. Acta Neurol Scand 2005; 112: 151-6
13. Rowan AJ, Gates JR. Non-epileptic seizures. Stoneham: Butterworth-Heinemann, 1993
14. Kotsopoulos I, de Krom M, Kessels F, et al. Incidence of epilepsy and predictive factors of epileptic and non-epileptic seizures. Seizure 2005; 14: 175-82
15. Niedermeyer ED. Electroencephalography and the diagnosis of epilepsy. In: Fisher RS, editor. Imitators of epilepsy. New York: Demos Publications, 1994: 227-80
16. Baumgartner C, Pataraia E. Revisiting the role of magnetoencephalography in epilepsy. Curr Opin Neurol 2006; 19: 181-6
17. Gotman J, Kobayashi E, Bagshaw AP, et al. Combining EEG and fMRI: a multimodal tool for epilepsy research. J Magn Reson Imaging. Epub 2006 Apr 28
18. Knowlton RC. The role of FDG-PET, ictal SPECT, and MEG in the epilepsy surgery evaluation. Epilepsy Behav 2006; 8: 91-101. Epub 2006 Jan 10
19. Johannessen SI. Plasma drug concentration monitoring of anticonvulsants. CNS Drugs 1997; 7: 349-65
20. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-63
21. Johannessen SI. Can pharmacokinetic variability be controlled for patient's benefit? The place of TDM for new AEDs. Ther Drug Monit 2005; 27: 10-3
22. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994; 35: 1026-102
23. McLean MJ, Macdonald RL. Carbamazepine and 10,11-epoxy-carbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 238: 727-38
24. Holmes GL. Carbamazepine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 285-97
25. Isojarvi JI, Tauboll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 2005; 19: 207-23
26. Johannessen SI. Pharmacokinetics of antiepileptic drugs and their clinical significance. Behav Neurol 1990; 3 Suppl. 1: 1-11
27. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Pt II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995; 29: 241-369
28. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996; 334: 168-75
29. Choonara IA, Rane A. Therapeutic drug monitoring of anticonvulsants: state of the art. Clin Pharmacokinet 1990; 18: 318-28
30. Mattson RH. Antiepileptic drug monitoring: a reappraisal. Epilepsia 1995; 36 Suppl. 5: S22-9
31. Johannessen SI, Tomson T. General principles: laboratory monitoring of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 103-11
32. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondary generalized tonic-clonic seizures. N Engl J Med 1985; 313: 145-51
33. Seltzer ME. The action of phenytoin on a composite electrical-chemical synapse in the lamprey spinal cord. Ann Neurol 1978; 3: 202-6
34. Bruni J, Wilder BJ. The toxicology of antiepileptic drugs. In: Viken PJ, Bruyn G, editors. Handbook of clinical neurology. Vol 37. Intoxications of the nervous system. Pt 20. New York: North-Holland Publishing Co., 1979: 199-222
35. Buchthal F, Svensmark O. Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia 1960; 1: 373-84
36. Mattson RH, Cramer JA, Collins JF, et al. A comparison of valproate with carbamazepine for complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327: 765-71
37. Johannessen CU, Petersen D, Fonnum F, et al. The acute effect of valproate on cerebral energy metabolism in mice. Epilepsy Res 2001; 47: 247-56
38. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-94
39. McLean MK, Macdonald RL. Sodium valproate, but not ethosuximide, produces use-and voltage-dependent limitation of high-frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237: 1001-11
40. Wilder BJ, Ramsay RE, Murphy JV, et al. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983; 33: 1474-6
41. Jeavons PM. Non-dose-related side effects of valproate. Epilepsia 1984; 25 Suppl. 1: 18-23S
42. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities II: US experience since 1984. Neurology 1988; 33: 201-7
43. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: Pt 1. Phenobarbital, primidone, valproic acid, ethosuximide, and mesuximide. Clin Pharmacokinet 1995; 29: 257-86
44. Gram L, Flachs H, Wurtz-Jorgensen A, et al. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979; 20: 303-11
45. Henriksen O, Johannessen SI. Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy. Acta Neurol Scand 1982; 65: 504-23
46. Sundqvist A, Tomson T, Lundkvist B. Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Ther Drug Monit 1997; 19: 153-9
47. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25: 213-20
48. Gallagher BB, Baumel IP, Mattson RH, et al. Primidone, diphenylhydantoin and phenobarbital: aspects of acute and chronic toxicity. Neurology 1973; 23: 145-9
49. Schottelius DD, Fincham RW. Clinical application of serum primidone levels. In: Pippenger CE, Penry JK, Kutt H, editors. Antiepileptic drugs: quantitative analysis and interpretation. New York: Raven Press, 1978: 273-82
50. Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and promidone. Epilepsia 1987; 28 Suppl. 3: S50-8
51. Robertson MM. Current states of the 1,4 and 1,5 benzodiazepines in the treatment of epilepsy: the place of clobazam. Epilepsia 1986; 27 Suppl. 1: 27-41S
52. Trimble MR. Clobazam. In: Resor SRJ, Kutt H, editors. The medical treatment of epilepsy. New York: Marcel Dekker Inc, 1992: 319-28
53. Koeppen DA. A review of clobazam studies in epilepsy. In: Hindmarch I, Stonier PD, Trimble MR, editors. Clobazam: Royal Society of Medicine International Congress Symposium Series No. 74. Lond R Soc Med 1985, 149-53
54. Wolf P. Clobazam in drug-resistant patients with complex focal seizures: report of an open study. In: Hindmarch I, Stonier PD, Trimble MR, editors. International Congress and Symposium Series No. 74. Lond R Soc Med 1985, 167-71
55. Streete JM, Berry DJ, Newbery JE. The analysis of clobazam and its metabolite desmethylclobazam by high-performance liquid chromatography. Ther Drug Monit 1991; 13: 339-44
56. Wang J, Hug D, Gautschi K, et al. Clobazam for treatment of epilepsy. J Epilepsy 1993; 6: 180-4
57. Dam M, Ekberg R, Loyning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6
58. Schmutz M, Brugger F, Gentsch C, et al. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilesia 1994; 35 Suppl. 5: 47-50S
59. Friis ML, Kristensen O, Boas J, et al. Therapeutic experience with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
60. Lloyd P, Flesch G, Dieterie W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: 10-13S
61. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35 Suppl. 3: 9-14S
62. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005; 27: 199-204
63. Van Parys JAP, Meinardi H. Survey of 260 patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 1994; 19: 79-85
64. Borusiak P, Korn-Merker E, Holert N, et al. Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 1998; 11: 355-60
65. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
66. Seino M, Fujitani B. Zonisamide: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, Perucca E. editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 885-91
67. Lee BI. Zonisamide: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E. editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 892-898
68. Leppik IE. Antiepileptic drugs in development: prospects for the near future. Epilepsia 1994; 35 Suppl. 4: 29-40S
69. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2005; (4): CD001416
70. Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy [published erratum appears in CNS Drugs 2005; 19: 633]. CNS Drugs 2005; 19: 347-67
71. Brodie M. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006; 68 Suppl. 2: S11-16
72. Ohtahara S. Zonisamide in the management of epilepsy: Japanese experience. Epilepsy Res 2006; 68 Suppl. 2: S25-33
73. Leppik IE. Practical prescribing and long-term efficacy and safety of zonisamide. Epilepsy Res 2006; 68 Suppl. 2: S17-24
74. Ito T, Yamaguchi T, Miyazaki H, et al. Pharmacokinetic studies of AD-810, a new antiepileptic compound: phase I trials. Arzneimittel Forschung 1982; 32: 1581-6
75. Sackellares JC, Donofrio PD, Wagner JG, et al. Pilot study of ZNS (1,2-benzisoxazole-3 methanesulfonamide) in patients with refractory partial seizures. Epilepsia 1985; 26: 206-11
76. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-7
77. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: re-examination its role in the treatment of epilepsy. Epilepsia 2000; 41 Suppl. 8: S6-15
78. Mumford JP, Lewis PJ. Vigabatrin. In: Pisani F, Perucca E, Avanzini G, et al., editors. New antiepileptic drugs. Epilepsy Res 1991; Suppl. 3: 161-8
79. Tartara A, Manni R, Galimberti CA, et al. Vigabatrin in the treatment of epilepsy: a double-blind placebo-controlled study. Epilepsia 1986; 27: 717-23
80. Ramsay RE, Slater JD. Antiepileptic drugs in clinical development. In: French JA, Dichter MA, Leppik IE, editors. New antiepileptic drug development, preclinical and clinical aspects. Epilepsy Res 1993; Suppl. 10: 45-67
81. Malmgren K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001; 4: 609-15
82. Kalviainen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15: 217-30
83. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27: 19-22S
84. Rimmer EM, Richens A. Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 1989; 27: 27-33S
85. Patsalos PN. New antiepileptic drugs. Ann Clin Biochem 1999; 36: 10-9
86. McKee PJW, Brodie MJ. Lamotrigine. In: Shorvon S, Dreifuss F, Fish D, et al., editors. The treatment of epilepsy. Oxford: Blackwell Science, 1996: 438-45
87. Yuen AWC. Lamotrigine. In: Pisani F, Perucca E, Avanzini G, et al., editors. New antiepileptic drugs. Epilepsy Res 1991; Suppl. 3: 115-23
88. Brodie MJ. Lamotrigine. Lancet 1992; 339: 1397-400
89. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-76
90. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570-1
91. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46: 1414-7
92. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7: 163-5
93. Depot M, Powell JR, Messenheimer Jr JA, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990; 48: 346-55
94. Ebert U, Thong NQ, Oertel R, et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000; 56: 299-304
95. Morris RG, Lee MY, Cleanthous X, et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 2004; 26: 626-32
96. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991; 41: 1785-9
97. Rho JM, Donevan SD, Rogawski MA. Felbamate inhibits NMDA responses and potentiates GABA responses in cultured rat hippocampal neurons [abstract]. Epilepsia 1993; 34 Suppl. 6: 119S
98. Pellock JM. Felbamate. Epilepsia 1999; 40 Suppl. 5: S57-62
99. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. Epub 2006 Apr 16
100. Leppik IE, Wolff DL. The place of felbamate in the treatment of epilepsy. CNS Drugs 1995; 4: 294-301
101. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996; 334: 1583-9
102. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-3
103. Anhut H, Ashman P, Feuerstein TJ, et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures; a double-blind, placebo-controlled study. Epilepsia 1994; 35: 795-801
104. Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95-9
105. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-27
106. Armijo JA, Pena MA, Adin J, et al. Association between patient age and gabapentin serum concentrations-to-dose ratio: a preliminary multivariate analysis. Ther Drug Monit 2004; 26: 633-7
107. Gatti G, Ferrari AR, Guerrini R, et al. Plasma gabapentin concentrations in children witn epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit 2003; 25: 54-60
108. Lindberger M, Luhr O, Johannessen SI, et al. Serum concentration and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit 2003; 4: 457-62
109. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600mg daily dosages. Neurology 1996; 46: 1684-90
110. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752-73
111. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit 2004; 26: 251-7
112. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763-80
113. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003; 25: 700-8
114. Dahlin MG, Öhman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol 2004; 4: 248-53
115. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet 2005; 44: 407-16
116. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977-80
117. Christensen J, Poulsen JH, Andreasen F, et al. Topiramate add-on treatment in refractory epilepsy patients: a randomised concentration controlled clinical trial [abstract]. Epilepsia 2001; 42 Suppl. 7: 178
118. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995; 36 Suppl. 6: 14-21S
119. Mengel H. Tiagabine. Epilepsia 1994; 35 Suppl. 5: 81-4S
120. Leppik IE. Tiagabine: the safety landscape. Epilesia 1995; 36 Suppl. 6: 10-13S
121. Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia 1997; 38 Suppl. 2: 23-7S
122. Schmidt D, Gram L, Brodie M, et al. Tiagabine in the treatment of epilepsy: a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245-51
123. Rowan AJ, Gustavson I, Shu V, et al. Dose concentration relationship in a multicenter tiagabine (Gabitril) trial [abstract]. Epilepsia 1997; 38 Suppl. 3: 40
124. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001; 42 Suppl. 4: 31-5
125. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs. Epilepsia 2001; 42 Suppl. 4: 13-8
126. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993; 232: 147-58
127. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (EILAT VII). Epilepsy Res 2004; 61: 1-48
128. Stables JP, Bialer M, Johannessen SI, et al. Progress report on new antiepileptic drugs: a summary of the second Eilat Conference. Epilepsy Res 1995; 22: 235-46
129. Harden C. Safety profile of levetiracetam. Epilepsia 2001; 42 Suppl. 4: 36-9
130. Patsalos PN. Pharmacokinetics profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85
131. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001; 42 Suppl. 4: 24-7
132. Data on file, UCB Pharma, Brussels, Belgium, 2001
133. Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs 2005; 19: 265-72
134. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl. 6: 13-8
135. Elger CE, Brodie MJ, Anhut H, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005; 46: 1926-36
136. Hamandi K, Sander JW. Pregabalin: a new antiepileptic drug for refractory epilepsy. Seizure 2006; 15: 73-8
137. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6: 108-13
138. Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit 2005; 27: 451-6
139. Musicco M, Beghi E, Solari A, et al. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997; 49: 991-8
140. Wiebe S. An evidence based approach to the first unprovoked seizure. Can J Neurol Sci 2002; 29: 120-4
141. Shinnar S, Berg AT, Moshe SL, et al. Risk of seizure recurrence following a first unprovoked seizure in childhood. Paediatrics 1990; 85: 1076-85
142. Hauser WA, Lee JR. Do seizures beget seizures? Prog Brain Res 2002; 135: 215-9
143. Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006; 19: 175-80
144. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000; 22: 75-80
145. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1261-73
146. Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004; 328: 1273-4
147. Scottish Intercollegiate Guidelines Network. Diagnoses and management of epilepsy [online]. Available from URL: http://www.sign.ac.uk/pdf/sign70.pdf [Accessed 2004 Jul 31]
148. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004; 3: 618-21
149. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilesia 2006; 47: 1094-120
150. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-74
151. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62: 1250-60
152. Zaccara G, Messori A, Cincotta M, et al. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurol Scand 2006: 114; 157-68
153. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 2001; 47: 17-25
154. Rowan AJ, Ramsay RE, Collins JF, et al. VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64: 1868-73
155. Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27: 205-13
156. Morrow JI, Russell A, Gutherie E, et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193-8
157. Vajda FJ, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005; 112: 137-43
158. Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38: 1039-41
159. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63: 571-3
160. Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11: 556-62
161. Krishnamoorthy ES. Psychiatric issues in epilepsy. Curr Opin Neurol 2001; 14: 217-24
162. Hauser WA, Lee JR. Do seizures beget seizures? Prog Brain Res 2002; 135: 215-9
163. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365: 2007-13
164. Kim LG, Johnson TL, Marson AG, et al. MRC MESS study group. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006; 5: 317-22
165. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-9
166. Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997; 26: 423-32
167. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile-myoclonic epilepsy of Janz. Neurology 1984; 34: 285-94
168. Chadwick D, Taylor J, Johnson T, et al. Outcomes after seizure recurrence in people with well controlled epilepsy and the factors that influence it. Drug Withdrawal Group. Epilepsia 1996, 50
169. Schmidt D, Loscher W. Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol Scand 2005; 111: 291-300
170. Pennell PB. Using current evidence in selecting antiepileptic drugs for use during pregnancy. Epilepsy Curr 2005; 5: 45-51